Source comparison
Tesamorelin Safety Profile: Adverse Event Comparison
Injection site reactions (erythema, pain, swelling) 35–40% Mild to moderate in 90% of cases Visual inspection at each injection; rotate sites ≥3cm apart Most common reason for temporary discontinuation; self-limiting within 5–7 days Glucose metabolism disturba
This comparison does not assign a generated winner or score.
- Injection site reactions (erythema, pain, swelling)
- 35–40%
- Mild to moderate in 90% of cases
- Visual inspection at each injection; rotate sites ≥3cm apart
- Most common reason for temporary discontinuation; self-limiting within 5–7 days
- Glucose metabolism disturbances (impaired fasting glucose, worsening diabetes)
- 5–8% (trials); 12–18% (real-world diabetic populations)
- Moderate; reversible upon discontinuation
- Fasting glucose and HbA1c at baseline, weeks 4, 12, 26
- Mechanism-driven through GH-induced insulin resistance; exclude HbA1c >8% at baseline
- Arthralgia and musculoskeletal pain
- 8–12%
- Mild; dose-dependent
- Patient-reported symptom tracking
- Associated with IGF-1 elevation; resolves with dose reduction
- IGF-1 elevation above normal range
- 15–20% (asymptomatic elevation)
- Variable; monitor for neoplastic risk
- IGF-1 level at baseline, week 12, week 26
- Contraindicated in active malignancy; requires imaging if pituitary symptoms develop
- Serious adverse events (pituitary hemorrhage, severe arthralgia)
- <2%
- Severe; requires immediate discontinuation
- Baseline pituitary MRI if history of headaches or visual disturbance
- Almost exclusively in patients with undiagnosed pituitary adenoma or extreme IGF-1 elevation